Former Alnylam CEO appointed new chair of Hemab

Biotech company Hemab starts the year by welcoming two new faces to the board, including former Alnylam CEO John Maraganore as chair. Hemab also appoints a new member to leadership.

Benny Sørensen, CEO of Hemab, is "delighted" to begin the new year by welcoming three new faces to Hemab | Photo: Hemab / PR

On Wednesday, biotech company Hemab presented a string of new people who will soon join either Hemab's board of directors or the company's management, as reported in a in a press release.

Former founding CEO of Alnylam John Maraganore will be the new chairman of the board, while Linda Bain, CFO of Codiak Biosciences, joins as a board member.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs